Open Access
13.01.2023 | COVID-19 | Short Communication
Left atrial strain is associated with distinct inflammatory and immune profile in patients with COVID-19 pneumonia
verfasst von:
Filipe André Gonzalez, Miguel Ângelo-Dias, Catarina Martins, Rui Gomes, Jacobo Bacariza, Antero Fernandes, Luis Miguel Borrego, EchoCrit Group
SARS-CoV-2 infection is associated with multiple cardiac manifestations. Left atrial strain (LA-S) by speckle tracking echocardiography (STE) is a novel transthoracic echocardiography (TTE) measure of LA myocardial deformation and diastolic dysfunction, which could lead to early recognition of cardiac injury in severe COVID-19 patients with possible implications on clinical management, organ dysfunction, and mortality. Cardiac injury may occur by direct viral cytopathic effects or virus-driven immune activation, resulting in heart infiltration by inflammatory cells, despite limited and conflicting data are available on myocardial histology.
Purpose
We aimed to explore LA-S and immune profiles in COVID-19 patients admitted to the intensive care unit (ICU) to identify distinctive features in patients with cardiac injury.
Methods
We enrolled 30 patients > 18 years with positive SARS-CoV-2 RT-PCR, admitted to ICU. Acute myocardial infarction and pulmonary embolism were exclusion criteria. On days D1, D3, and D7 after ICU admission, patients performed TTE, hemogram, cardiac (pro-BNP; troponin) and inflammatory biomarkers (ESR; ferritin; IL1β; IL6; CRP; d-dimer; fibrinogen; PCT; adrenomedullin, ADM), and immunophenotyping by flow cytometry.
Results
Patient’s mean age was 60.7 y, with 63% males. Hypertension was the most common risk factor (73%; with 50% of patients under ACEi or ARA), followed by obesity (40%, mean BMI = 31 kg/m2). Cardiac dysfunction was detected by STE in 73% of patients: 40% left ventricle (LV) systolic dysfunction, 60% LV diastolic dysfunction, 37% right ventricle systolic dysfunction. Mortality, hospitalization days, remdesivir use, organ dysfunction, cardiac and serum biomarkers were not different between patients with (DYS) and without cardiac dysfunction (nDYS), except for ADM (increased in nDYS group at D7). From the 77 TTE, there was a striking difference between diastolic dysfunction evaluation by classic criteria compared to STE (28.6% vs. 57.1%, p = 0.0006). Lower reservoir (Ɛ) and contraction (ƐCT) LA-S correlated with IL-6 (Ɛ, p = 0.009, r = − 0.47; ƐCT, p = 0.0002, r = − 0.63) and central memory CD4 T-cells (ƐCT, p = 0.049, r = − 0.24). Along all timepoints, DYS patients showed persistent low lymphocyte counts that recovered at D7 in nDYS patients. DYS patients had lower platelets at D3 and showed a slower recovery in platelet counts and CRP levels; the latter significantly decreased at D7 in nDYS patients (p = 0.009). Overall, patients recovered with an increasing P/F ratio, though to a lesser extent in DYS patients.
Discussion
Our study shows that LA-S may be a more sensitive marker for diastolic dysfunction in severe COVID-19, which could identify patients at risk for a protracted inflammatory state. A differential immune trait in DYS patients at ICU admission, with persistent lymphopenia, enriched CM T-cells, and higher IL-6 may suggest distinct inflammatory states or migration patterns in patients that develop cardiac injury.
Hinweise
This project occurred in the Intensive Care Department in Hospital Garcia de Orta, Almada, Portugal
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Introduction
In severe COVID-19 patients, diagnostic transthoracic echocardiography (TTE) allows early recognition of cardiac injury with an impact on clinical management, reducing organ dysfunction and mortality [1, 2]. Notably, the expression of the cardiovascular disease seems to be a marker of a poor prognosis in COVID-19 [3]. More recently, the assessment of left atrial strain (LA-S), assessed by speckle tracking echocardiography (STE), has allowed a more accurate and reproducible analysis of left atrial function [4], correlating more accurately with left ventricle (LV) diastolic dysfunction (LVDD) [5] and with invasive hemodynamics [6]. By measuring less explored diastolic dysfunction parameters, such as LA-S, a broader spectrum of cardiac dysfunction may be recognized, allowing earlier and more effective management in COVID-19 patients.
Here, we aimed to explore diastolic dysfunction parameters and the immune profile in COVID-19 patients admitted to the intensive care unit (ICU) to identify distinctive immune features in patients with cardiac injury.
Anzeige
Materials and methods
We enrolled 30 patients > 18 years with positive SARS-CoV-2 RT-PCR test who were admitted to ICU between March and September 2022. Acute myocardial infarction and pulmonary embolism were exclusion criteria. On days D1, D3, and D7 after ICU admission, patients performed STE, hemogram, cardiac (pro-BNP; troponin) and inflammatory biomarkers (ESR; ferritin; IL1β; IL6; CRP; d-dimer; fibrinogen; PCT; adrenomedullin, ADM), and immunophenotyping by flow cytometry.
The presence of cardiac dysfunction (DYS vs. nDYS) was classified according to the European Society of Cardiology (ESC) and American Society of Echocardiography (ASE) guidelines for chamber quantification classification [7]: LV systolic dysfunction (LVSD) was defined as a calculated LVEF < 50% or LVGLS < 20%; RV systolic dysfunction was defined as RV FAC < 35%, TAPSE < 17 mm, S’ < 9.5 cm/s or RVGLS < 20%. LVDD dysfunction was classified by “classic” criteria according to 2016 ASE/EACVI guidelines [8] and by LA-S to assess contractile (ƐCT < 10%) and reservoir (Ɛ < 30%) functionality using definitions from previous studies [9] (Fig. 1).
Fig. 1
Left atrium strain example with reservoir (Ɛ) and contraction (ƐCT) functions highlighted
×
Results
The patient’s mean age was 60.7 years, with 63% males. Hypertension was the most common risk factor (73%, of which 50% of were under ACEi or ARA), followed by obesity (40%, mean BMI = 31 kg/m2). Cardiac dysfunction was detected by STE in 73% of patients: 40% LVSD, 60% LVDD, 37% right ventricle systolic dysfunction. Mortality, hospitalization days, remdesivir use, organ dysfunction, and cardiac and serum biomarkers were not different between patients with and without cardiac dysfunction. The 77 TTE evaluations showed a striking difference between diastolic dysfunction evaluation by classic criteria compared to LA-S (28.6% vs. 57.1%, p = 0.0006).
When comparing classic LVDD with LA-S LVDD (Table 1), the latter discriminated longer IVCT (DYS: 70 ms [51–79] vs. nDYS: 50 ms [42–64]) and pre-TE (DYS: 74 ms [67–88) vs. nDYS: 63 ms [42.5–81]), and slightly worse RV systolic function (RV FAC DYS: 41.51% [33.59–48.03] vs. nDYS: 48.61% [40.96–58.32]; RV GLS DYS: 21.85% [18.5–29.24] vs. nDYS: 26.95% [22.38–31.59]) and lower CI (DYS: 2.47 l/min/m2 [2.01–2.92] vs. nDYS: 2.83 l/min/m2 [2.24–4.11]).
Table 1
Comparison of echocardiographic, hemodynamic parameters and cardiac biomarkers between left ventricle diastolic dysfunction by classic criteria vs. left atrium strain
All evaluations median (IQR)
Classic DYS (n = 22)
Classic nDYS (n = 55)
Classic DYS vs. nDYS*
Strain DYS (n = 44)
Strain nDYS (n = 33)
Strain DYS vs. nDYS*
Classic DYS vs. strain DYS*
LVEF (%)
55.08 (40.40–63.08)
51.93 (45.02–60.04)
n.s
51.98 (41.40–60.49)
52.67 (47.32–61.64)
n.s
n.s
LV GLS (%)
24.66 (20.85–30.19)
24.06 (20.28–27.80)
n.s
23.72 (18.71–29.00)
25.16 (21.63–28.00)
n.s
n.s
MAPSE (mm)
16.50 (14.70–17.98)
16.20 (15.00–17.80)
n.s
16.05 (14.93–18.25)
16.30 (15.00–17.80)
n.s
n.s
LA-ƐCT (%)
9.66 (6.65–13.23)
11.10 (6.20–15.23)
n.s
6.75 (4.63–9.74)
14.50 (12.69–18.63)
< 0.0001
0.0577
LA-Ɛ (%)
26.35 (21.13–29.07)
30.00 (19.80–38.42)
0.0582
22.15 (17.80–27.30)
37.50 (33.25–42.01)
< 0.0001
0.0403
LV A (cm/s)
78.20 (57.95–90.75)
63.45 (55.78–81.98)
n.s
66.35 (55.40–82.25)
64.20 (57.55–93.65)
n.s
n.s
LV E (cm/s)
59.00 (53.75–78.30)
73.10 (63.20–84.60)
0.0041
67.85 (57.45–79.65)
71.50 (60.25–83.30)
n.s
n.s
LV E/A
0.74 (0.62–1.08)
1.08 (0.89–1.33)
0.0005
0.97 (0.76–1.36)
1.03 (0.82–1.29)
n.s
0.0288
LV e' lat (cm/s)
9.65 (7.15–10.78)
10.80 (9.20–12.80)
0.0114
10.45 (8.13–12.80)
9.80 (9.00–11.45)
n.s
n.s
LV e' sep (cm/s)
6.60 (5.80–8.10)
8.50 (7.00–10.10)
0.0087
7.78 (6.50–11.50)
7.90 (6.50–9.20)
n.s
n.s
LV E/e'
7.62 (5.91–9.39)
7.63 (6.72–9.15)
n.s
7.58 (6.24–9.27)
7.80 (6.81–9.20)
n.s
n.s
LV IVCT (msec)
67.00 (51.00–79.00)
85.00 (71.00–103.50)
n.s
70.00 (51.00–79.00)
50.00 (42.00–64.00)
0.0018
n.s
LV pre-ET (msec)
71.50 (56.00–81.25)
71.00 (54.00–88.00)
n.s
74.00 (67.00–88.00)
63.00 (42.50–81.00)
0.0297
n.s
RV FAC (%)
42.34 (31.21–51.15)
43.03 (40.13–52.28)
n.s
41.51 (33.59–48.03)
48.61 (40.96–58.32)
0.0022
n.s
RV GLS (%)
25.99 (19.11–34.27)
24.03 (18.89–29.22)
n.s
21.85 (18.50–29.24)
26.95 (22.38–31.59)
0.0303
n.s
TAPSE (mm)
21.10 (18.88–23.35)
22.30 (20.50–25.00)
n.s
21.55 (19.45–23.35)
22.80 (20.60–25.10)
n.s
n.s
RV S' (cm/s)
14.90 (13.25–16.28)
15.90 (12.40–18.00)
n.s
14.90 (12.65–17.45)
15.80 (12.50–17.60)
n.s
n.s
RV e' (cm/s)
9.40 (6.68–13.43)
10.20 (8.00–14.40)
n.s
11.25 (8.70–14.98)
9.50 (7.65–12.70)
0.0331
n.s
CI (l/min/m2)
2.47 (1.99–3.42)
2.67 (2.20–3.04)
n.s
2.47 (2.01–2.92)
2.83 (2.24–4.11)
0.0473
n.s
NTproBNP (pg/ml)
275.00 (95.30–643.80)
214.00 (84.00–923.00)
n.s
229.50 (79.05–1016.00)
262.00 (107.00–650.00)
n.s
n.s
Troponin (ng/l)
13.00 (13.00–15.17)
13.00 (13–23.70)
n.s
13.00 (13.00–16.55)
13.10 (13.00–20.14)
n.s
n.s
DYS, cardiac dysfunction; nDYS, no cardiac dysfunction; LV, Left ventricle; LVEF, LV ejection fraction; LV GLS, LV global longitudinal strain; MAPSE, Mitral annular plane systolic excursion; LA, Left atrium; LA ƐCT, LA strain contraction function; LA Ɛ, LA strain reservoir function; LV A, LV Atrial contraction wave; LV E, LV Early diastolic filling wave; LV E/A, LV E wave to A wave ratio; LV e' lat, LV tissue doppler lateral e wave; LV e' sep, LV tissue doppler septal e wave; LV E/'e', LV E wave to tissue doppler e wave ratio; LV IVCT, LV isovolumetric contraction time; LV pre-ET, LV pre-ejection time; RV, Right ventricle; RV FAC, RV Fractional area change; RV GLS, RV Global longitudinal strain; TAPSE, Tricuspid annular plane systolic excursion; RV S', RV tissue doppler S wave; RV e', RV tissue doppler lateral e wave; CI, Cardiac index; NTproBNP, NT terminal of prohormone brain natriuretic peptide
*Mann–Whitney test
Anzeige
Discussion
Our data regarding cardiac dysfunction prevalence in COVID-19 patients is in line with recent evidence, suggesting that 70% of patients with COVID-19 harboured a cardiac injury within the first ICU admission, identified by multimodal cardiac assessment [10]. This incidence is higher than other previously reported values that ranged from 12 to 30% [11‐13]. The higher incidence reported by Doyen and collaborators [10] could be explained by either the longitudinal cardiac assessment or the use of a much more sensitive tool to detect LV diastolic dysfunction, as is the STE [5], being simultaneously in line with incidences reported in critically ill patients with sepsis not related to COVID-19 [14]. Thus, it confirms that COVID-19 patients experienced more LV diastolic than systolic dysfunction [15].
Diastolic dysfunction is an elusive pathological condition due to the late definition of its diagnostic criteria, and these strict classical parameters are difficult to apply to critically ill patients, compromising its classification. Recently, some studies have tried to overcome this issue by simplifying and validating specific criteria. Clancy et al. [16] applied the 2016 America Society of Echocardiography (ASE)/European Association of Cardiovascular Imaging (EACVI) guidelines, comparing with the previous 2009 ASE guidelines, achieving 60% of diastolic dysfunction on the first day, with a further 23% having an indeterminate diastolic function, where only 21% had confirmed diastolic dysfunction with 74% having indeterminate diastolic dysfunction, respectively. In addition, Lanspa et al. [17] proposed a simplified definition using only e′ and E/e′, categorizing 87% of patients, compared with 35% of patients using ASE 2009 guidelines. Both groups had similar clinical outcomes. Nevertheless, the massive diffusion of echocardiography provides a more precise appreciation of its burden in critically ill patients. Recently, Filippo Sanfilippo et al. reviewed and explained extensively the challenges of diagnosing diastolic dysfunction in critically ill patients [18].
In this context, a systematic echocardiographic evaluation of 100 COVID-19 patients by Szekely et al. revealed a LVDD as high as 90% in their cohort with a mean age of 66 years, despite a preserved LV ejection fraction [19]. Alongside the subclinical ventricular relaxation impairment (given the advanced age and co-morbidities such as systemic hypertension), the conglomeration of factors specific to COVID-19 such as systemic inflammatory milieu, endothelial dysfunction, microvascular thrombosis, arrhythmias, disturbed ventricular cross-talk (owing to the concomitant right ventricular dysfunction resulting from pulmonary hypertension), and myocardial oxygen supply–demand perturbations, can contribute significantly to the LVDD with a subsequent accentuated potential to culminate as heart failure with preserved ejection fraction (HFpEF) [15].
Few studies have addressed the evolution of the immune profile in COVID-19 patients with cardiac injury. Namely, Laing et al. [20] accomplished an exhaustive immunological analysis, where they identified discrete changes in the compartments of circulating B and myelomonocytic cells, along with profoundly altered T cell phenotypes, upregulation of several cytokines/chemokines and SARS-CoV-2-specific antibodies. Moreover, another group studied the association between the immune profile and cardiac injury in COVID-19 patients, suggesting that the numbers of T and B lymphocytes were significantly decreased in the group with cardiac injury [21].
Our study shows that LA-S may be a more sensitive marker for diastolic dysfunction in severe COVID-19, identifying patients at risk for a protracted inflammatory state.
In fact, we have previously described that a differential immune trait is present in patients at ICU admission, with persistent lymphopenia, enriched central memory CD4 T cells, and higher serum levels of IL-6, suggesting a distinct inflammatory state and migration patterns in patients that develop cardiac injury [22]. Thus, an improved comprehension of the likelihood of an altered diastology in COVID-19 patients is doubtlessly pivotal in staging a more well-directed management approach, wherein targeted echocardiographic surveillance, cardiac and immune-inflammatory biomarkers, combined heart–lung ultrasound and inodilators, can assist the overall management of this critically ill cohort.
Within our limitations, it is worth mentioning the small sample size that could have underpowered our study for more clinically significant outcomes such as mortality, mechanical ventilation, shock, ICU and hospital length of stay. Nevertheless, the repeated measures along the time course may have partially overcome this issue for the other results.
Conclusions
Our study shows that LA-S may be a more sensitive marker for diastolic dysfunction in severe COVID-19, particularly patients at ICU admission with persistent lymphopenia, enriched CM T-cells, and higher IL-6, which may suggest a differential immune trait in cardiac injury COVID-19 patients in ICU.
Anzeige
Acknowledgements
The authors thank Pedro Pereira from Canon, Portugal, for providing the 2D Wall Motion Tracking software for speckle tracking echocardiography.
The EchoCrit Group is a collaboration group of the Intensive Care Department of Hospital Garcia de Orta, Almada, Portugal, dedicated to the advanced Echocardiography and POCUS in critical care, formed by the following physicians: Rui Gomes, Jacobo Bacariza, Rita Varudo, João Leote, Vera Pereira, Dário Batista, Vânia Brito, Corinna Lohmann, João Gouveia, Joana Manuel, Liliana Santos, Sara Lança, Lucinda Oliveira, Tiago Ferreira, Joana Ferreira, João Sampaio, José Seoane, Inês Pimenta, Cristina Martins, Ricardo Meireles, Francisco D’Orey, Maria Inês Ribeiro, Antero Fernandes (Head of Intensive Care Department). The authors would like the names of the individual members of the Group to be searchable through their individual PubMed records.
Declarations
Ethics approval and consent to participate
This was a prospective observational study on current practice, and all collected data were the standard monitoring and intervention data used in critical care. All monitoring and intervention attitudes have been extensively described in the literature, and patients were assessed and treated routinely. Data were anonymously collected, and all information allowing patient identification was not collected. Patient anonymity was maintained both during data processing and publishing. A patient number was used in all echocardiograms recorded for later review by an expert. According to local legislation, consent from the patient or next of kin to record data and to draw blood was obtained before study enrolment, and the Ethics Committees approved the study of Hospital Garcia de Orta and NOVA Medical School (CE nº 44-2020-CEFCM).
Consent for publication
All the patients (or next of kin) signed a consent form for personal data collection and scientific use, such as publication. Nevertheless, all information that eventually can identify the patient is anonymized or not published.
Anzeige
Competing interests
The authors declare that they have no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.
Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.
Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.
„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.
Update Innere Medizin
Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.
